AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

DCOY · NASDAQ · Biotechnology

Decoy Therapeutics (DCOY)

Developer of peptide-conjugate antivirals against shared viral fusion machinery.

$2.82

Pre-market−0.17 (−5.69%)

At close$2.99(−2.29%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

Institutions4 holders · as of Mar 31, 2026	0.25%	1.6K shares
Insiders10 holders · as of Sep 2, 2026	10.56%	69.2K shares
Strategic holders1 holder · as of Aug 14, 2026	10.00%	65.5K shares
Otherremainder	79.19%	518.9K shares

655.2K company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Two share counts disagree (655.2K in the company's Sep 3, 2026 report, 532.0K elsewhere); stakes use the report.

A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Armistice Capital, LLCStrategic	10.00%	65,503	13Gfiled Aug 14, 2026 ↗
Frederick Ii PierceInsiderofficer: Chief Executive Officer	5.32%	34,844	Form 4filed Sep 2, 2026 ↗
Mark J. RosenblumInsiderofficer: Chief Financial Officer	1.73%	11,363	Form 4filed Sep 2, 2026 ↗
Barbara Louise HibnerInsiderofficer: Chief Scientific Officer	0.64%	4,216	Form 4filed Sep 2, 2026 ↗
Peter Klaus MarschelInsiderofficer: Chief Business Officer	0.60%	3,900	Form 4filed Sep 2, 2026 ↗
Arnold C. HanishInsiderdirector	0.59%	3,835	Form 4filed Sep 2, 2026 ↗
William K. McVicarInsiderdirector	0.46%	3,002	Form 4filed Sep 2, 2026 ↗
Tess BurlesonInsiderdirector	0.31%	2,002	Form 4filed Sep 2, 2026 ↗
Jonathan I. LieberInsiderdirector	0.31%	2,002	Form 4filed Sep 2, 2026 ↗
Paul LammersInsiderdirector	0.31%	2,001	Form 4filed Sep 2, 2026 ↗
Patricia G. GauthierInsiderdirector	0.31%	2,000	Form 4filed Sep 2, 2026 ↗
Tower Research Capital LLC (TRC)Institution	0.16%	1,021	13Fas of Mar 31, 2026
UBS Group AGInstitution	0.08%	546	13Fas of Mar 31, 2026
Advisory Services Network, LLCInstitution	0.01%	41	13Fas of Mar 31, 2026
Morgan StanleyInstitution	0.00%	1	13Fas of Mar 31, 2026
CVI Investments, Inc.Strategic	—9.90% of class, as filed	—	13Gfiled Feb 17, 2026 ↗
David J. Arthur¹Insiderdirector, officer: Chief Executive Officer	0.01%	33	Form 4filed Feb 15, 2023 ↗
Jonathan P. Northrup²Insiderdirector	0.00%	10	Form 4filed Feb 12, 2020 ↗
Boston Foundation, Inc.³Strategic10 percent owner	0.00%	2	Form 4filed Jan 10, 2019 ↗
Bruce J. Jr. McCreedy⁴Insiderdirector	0.00%	1	Form 4filed Jan 5, 2023 ↗
Scott Jordan⁵Insiderofficer: Chief Business Officer	0.00%	1	Form 4filed Feb 18, 2020 ↗
Christoph H. Westphal⁶Insider10 percent owner	0.00%	0	Form 4filed Dec 21, 2018 ↗
Roger D. Tung⁷Insiderdirector	0.00%	0	Form 4filed Nov 6, 2017 ↗
John P. McCabe⁸Insiderofficer: VP of Finance & Treasurer	0.00%	0	Form 4filed Nov 7, 2016 ↗
Longwood Fund II, L.P.⁹Strategic10 percent owner	0.00%	0	Form 4filed Oct 18, 2018 ↗

Last filed Feb 15, 2023; leaving the company requires no filing. Not in the bar.
Last filed Feb 12, 2020; leaving the company requires no filing. Not in the bar.
Last filed Jan 10, 2019; leaving the company requires no filing. Not in the bar.
Last filed Jan 5, 2023; leaving the company requires no filing. Not in the bar.
Last filed Feb 18, 2020; leaving the company requires no filing. Not in the bar.
Last filed Dec 21, 2018; leaving the company requires no filing. Not in the bar.
Last filed Nov 6, 2017; leaving the company requires no filing. Not in the bar.
Last filed Nov 7, 2016; leaving the company requires no filing. Not in the bar.
Last filed Oct 18, 2018; leaving the company requires no filing. Not in the bar.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

4 holders · 1.6K shares

Holder	Shares	% outstanding	Filed
Tower Research Capital LLC (TRC)	1.0K	0.16%	May 15, 2026
UBS Group AG	546	0.08%	May 5, 2026
Advisory Services Network, LLC	41	0.01%	May 15, 2026
Morgan Stanley	1	0.00%	May 15, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
Armistice Capital, LLC	9.99%	65.5K	13G	Aug 14, 2026 ↗
CVI Investments, Inc.	9.90%		13G	Feb 17, 2026 ↗

Insider tradesForm 4

Latest trades

Date	Insider	Type	Shares	Avg price	Owned after
Dec 30, 2025	Arnold C. Hanishdirector	Sale · 2 lots	27	$0.6397	5,000
Nov 20, 2025	Arnold C. Hanishdirector	Purchase	5,000	$0.7481	5,015
Nov 20, 2025	Mark J. Rosenblumofficer: Exec VP Finance, CFO	Purchase	20,000	$0.8000	20,177

CongressHouse and Senate disclosures

Not reported.